Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: B01AD13Orphan Medicine

Adzynma(rADAMTS13)

Purpura, Thrombotic Thrombocytopenic

Marketing Authorisation Holder: Takeda Manufacturing Austria AG

EMA Authorisation: 01/08/2024

INN: rADAMTS13

Indication

Treatment of congenital thrombotic thrombocytopenic purpura (cTTP) due to ADAMTS13 deficiency

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Adzynma — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.